Literature DB >> 11788817

PET imaging in breast cancer.

E Bombardieri1, F Crippa.   

Abstract

The basis of tumour imaging with PET is a specific uptake mechanism of positron emitting radiopharmaceuticals. Among the potential tracers for breast cancer (fluorodeoxyglucose, methionine, tyrosine, fluoro-estradiol, nor-progesterone), 2-deoxy-2-fluoro-D-glucose labelled with fluorine (FDG) is the most widely used radiopharmaceutical because breast cancer is particularly avid of FDG and 18F has the advantages of a relatively long physical half-life. Mammography is the first choice examination in studying breast masses, due to its very good performances, an excellent compliance and the best value regarding the cost/effectiveness aspects. However FDG-PET revealed to be effective in the study of patients with ambiguous mammographies. The FDG uptake in tissue correlates with the histological grade and potential aggressiveness of breast cancer and this may have prognostic consequences. Besides the evaluation of breast lesions, FDG-PET shows a great efficacy in staging lymph node involvement prior surgery and this could have a great value in loco-regional staging. Whole body PET provides also information with regard to metastasis localizations both in soft tissue and bone, and plays an important clinical role mainly in detecting recurrent metastatic disease. In fact for its metabolic characteristics PET visualizes regions of enhanced metabolic activity and can complements other imaging modalities based on structural anatomic changes. Even though CT and MRI show superior resolution characteristics, it has been demonstrated that PET provides more accurate information in discriminating between viable tumour, fibrotic scar or necrosis. Several clinical evidences demonstrated that FDG-PET is also able to predict wether cancer will respond to the therapy, or, when applied at the end of the treatment, it can assess the response to the therapy. These statements are coming from the examination of more than 2000 breast cancer patients included in 88 articles or abstracts on studies in which FDG-PET was used for breast cancer detection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11788817

Source DB:  PubMed          Journal:  Q J Nucl Med        ISSN: 1125-0135


  11 in total

1.  Breast scintigraphy: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

2.  Evaluation of novel genetic algorithm generated schemes for positron emission tomography (PET)/magnetic resonance imaging (MRI) image fusion.

Authors:  K G Baum; E Schmidt; K Rafferty; A Krol; María Helguera
Journal:  J Digit Imaging       Date:  2011-12       Impact factor: 4.056

Review 3.  Advantages and limitations of FDG PET in the follow-up of breast cancer.

Authors:  Peter Lind; Isabel Igerc; Thomas Beyer; Peter Reinprecht; Klaus Hausegger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

Review 4.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

5.  Differentiation of benign and malignant breast tumors by in-vivo three-dimensional parallel-plate diffuse optical tomography.

Authors:  Regine Choe; Soren D Konecky; Alper Corlu; Kijoon Lee; Turgut Durduran; David R Busch; Saurav Pathak; Brian J Czerniecki; Julia Tchou; Douglas L Fraker; Angela Demichele; Britton Chance; Simon R Arridge; Martin Schweiger; Joseph P Culver; Mitchell D Schnall; Mary E Putt; Mark A Rosen; Arjun G Yodh
Journal:  J Biomed Opt       Date:  2009 Mar-Apr       Impact factor: 3.170

6.  Targeting the alphavbeta3 integrin for small-animal PET/CT of osteolytic bone metastases.

Authors:  Thaddeus J Wadas; Hongju Deng; Jennifer E Sprague; Alexander Zheleznyak; Katherine N Weilbaecher; Carolyn J Anderson
Journal:  J Nucl Med       Date:  2009-11       Impact factor: 10.057

7.  Preoperative evaluation of prognosis in breast cancer patients by [(18)F]2-Deoxy-2-fluoro-D-glucose-positron emission tomography.

Authors:  Tomoo Inoue; Kenji Yutani; Tetsuya Taguchi; Yasuhiro Tamaki; Eiichi Shiba; Shinzaburo Noguchi
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-24       Impact factor: 4.553

8.  The Effects of Preoperative (18)F-FDG PET/CT in Breast Cancer Patients in Comparison to the Conventional Imaging Study.

Authors:  Young Jin Choi; Young Duck Shin; Yoon Hee Kang; Moon Soo Lee; Min Koo Lee; Byung Sun Cho; Yoon Jung Kang; Ju Seung Park
Journal:  J Breast Cancer       Date:  2012-12-31       Impact factor: 3.588

9.  Multicellular tumour spheroid as a model for evaluation of [18F]FDG as biomarker for breast cancer treatment monitoring.

Authors:  Azita Monazzam; Pasha Razifar; Martin Simonsson; Fredrik Qvarnström; Raymond Josephsson; Carl Blomqvist; Bengt Långström; Mats Bergström
Journal:  Cancer Cell Int       Date:  2006-03-23       Impact factor: 5.722

10.  Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.

Authors:  Renee M Moadel; Andrew V Nguyen; Elaine Y Lin; Ping Lu; Joseph Mani; M Donald Blaufox; Jeffrey W Pollard; Ekaterina Dadachova
Journal:  Breast Cancer Res       Date:  2003-08-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.